- Expands its portfolio to deliver high-quality drugs at an affordable cost
· India becomes the first market to witness Lilly’s entry in the branded generics segment
· Announces launch of drugs in Breast cancer and Colo-rectal cancer segment
Lilly has been dedicated to delivering solutions that accelerate the pace and progress of cancer care and enhance the lives of people living with cancer. In India, Lilly has cultivated a strong equity in the Lung Cancer segment with innovative brands Gemcite and Alimta. With launch of Lil Therapeutics, Lillyaims to expand patients’ access to high-quality cancer drugs.
Commenting on the development, Mr. Edgard A Olaizola, Managing Director, Eli Lilly says “ Lilly is committed to improving outcomes for individual patients around the world. We understand that Cancer medicines of the highest quality continue to be an unmet need in India a nd as a responsible organization, we have been working over the years to make cancer drugs affordable to better serve Indian patients. This launch reaffirms our commitment to reach more patients and play a leading role in fighting cancer in this country”. He also mentioned, “ Though Lilly is launching branded generics in the oncology segment, we will continue to discover and develop innovative new therapies for patients worldwide.”
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs. Additional information about Lilly is available at www.lilly.com
